baricitinib - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.54 [0.31, 0.95]< 10%1 study (1/-)98.4 %lownot evaluable highcrucial-
deaths 0.54 [0.31, 0.95]< 10%1 study (1/-)98.4 %lownot evaluable highcrucial-
clinical improvement 2.87 [1.12, 7.36]> 10%1 study (1/-)98.6 %lownot evaluable highimportant-
clinical improvement (14-day) 1.97 [0.95, 4.09]> 10%1 study (1/-)96.6 %lownot evaluable highimportant-
clinical improvement (28-day) 1.82 [0.87, 3.81]> 10%1 study (1/-)94.4 %lownot evaluable highimportant-
recovery 1.57 [0.77, 3.20]> 10%1 study (1/-)89.3 %lownot evaluable highnon important-

safety endpoints 00

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.